Emmaus Life SciencesEMMA Days Inventory is 940.74 as of Mar. 2026, which is 49% above its 10-year median of 632.52. The stock has 6 warning signs investors should review. Among 640 Biotechnology companies, Emmaus Life Sciences ranks worse than 86.09% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Emmaus Life Sciences's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.10.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emmaus Life Sciences's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.87.
Emmaus Life Sciences (OTCPK:EMMA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Emmaus Life Sciences's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emmaus Life Sciences's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Emmaus Life Sciences Days Inventory Related Terms
Emmaus Life Sciences Days Inventory Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMMA vs CERO, AGTX, WINT: Days Inventory Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Days Inventory of 940.74 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Emmaus Life Sciences and its competitors. This is 49% above median its historical median of 632.52. Over the past decade, Emmaus Life Sciences' Days Inventory has ranged from 477.48 to 2,659.43. According to the industry distribution chart, Emmaus Life Sciences ranks #551 out of 640 companies in the Biotechnology industry, placing it in the top 86.1%.
Is Emmaus Life Sciences' Days Inventory too high?
Emmaus Life Sciences' current Days Inventory of 940.74 is 49% above median its 10-year median of 632.52. Over the past 10 years, this metric has ranged from a low of 477.48 to a high of 2,659.43. The Biotechnology industry median Days Inventory is 184.15. Emmaus Life Sciences' value of 940.74 is 410.9% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #551 out of 640 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' Days Inventory compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #551 out of 640 companies for Days Inventory. This places Emmaus Life Sciences in the lower half of its industry. The industry median Days Inventory is 184.15. Emmaus Life Sciences' value of 940.74 is 410.9% above this benchmark. Historically, Emmaus Life Sciences' own Days Inventory has ranged from 477.48 to 2,659.43 over the past decade. While the company's 10-year median is 632.52 vs. the industry median of 184.15, Emmaus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Days Inventory of 940.74 is 410.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Days Inventory is 940.74, which is 49% above median its own 10-year median of 632.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Days Inventory is 940.74, which is 49% above median its 10-year median of 632.52 and 410.9% above the Biotechnology industry median of 184.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Days Inventory is 940.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 